Taiga Biotechnologies

Taiga Biotechnologies is a clinical stage biotechnology company headquartered in the United States. Founded in 2006, the company focuses on leveraging the potential of the immune system to combat solid tumors and infectious diseases while also striving to enhance blood stem cell transplantation.

The company's flagship product candidate, TBX-3400, is a Cell-Based Immunotherapy treatment that utilizes the patient's own immune cells to target solid tumors and infectious diseases. What sets TBX-3400 apart is its ability to avoid the need for extensive T-cell expansion in the laboratory, engineering T-cell specificity, or genetic modification of T-cells to enable antitumor activity.

In addition to its immunotherapy program, Taiga Biotechnologies is also advancing the Bone Marrow Engraftment Enhancer (BMEE) program, which aims to develop TBX-2400 to improve the engraftment of hematopoietic stem and progenitor cells during allogeneic hematopoietic stem cell transplants. The ultimate goal of the BMEE program is to increase the likelihood of long-term survival for HSCT recipients by enhancing engraftment success and managing associated complications.

In August 2020, the company secured a $13.96M Debt Financing investment. While the specific investors for this round are not disclosed, this funding highlights the investor confidence in Taiga Biotechnologies' innovative approach to harnessing the immune system for medical advancements.

Taiga Biotechnologies' commitment to revolutionizing immunotherapy and stem cell transplantation makes it a compelling prospect for potential investors seeking to support groundbreaking solutions in the biotechnology industry.